Skip to main content
Fig. 2 | European Journal of Medical Research

Fig. 2

From: Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma

Fig. 2

Overall survival (OS) and progression-free survival (PFS) according to subgroup analysis. OS of the PD-1 inhibitor monotherapy cohort (A) and of the PD-1 inhibitor combined with targeted therapy cohort (B); PFS of the PD-1 inhibitor monotherapy cohort (C) and of the PD-1 inhibitor combined with targeted therapy cohort (D)

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us